Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Do Symptoms and Quality of Life Differ between Focal and Diffuse Coronary Artery Disease?

Changes in fractional flow reserve (FFR) values after percutaneous coronary intervention (PCI) are associated with improvement in angina symptoms. The pattern of baseline coronary artery disease influences the degree of variation in FFR after stent implantation.

La coronariografía precoz reduce la mortalidad en SCA sin supradesnivel del ST de alto riesgo

Focal coronary artery disease leads to high post-PCI FFR values, while the improvement is not as marked in diffuse coronary artery disease. Baseline pattern of coronary disease can anticipate the likelihood of successful improvement in angina symptoms. However, the definition of diffuse disease has not been standardized and is often based on visual assessment, limiting its accuracy and repeatability.

Using the pullback pressure gradient (PPG) of the FFR, the aim of this subanalysis of the randomized, prospective, single-center study TARGET-FFR (Trial of Angiography vs. pressure-Ratio-Guided Enhancement Techniques-Fractional Flow Reserve) was to investigate the differential effect on patient-reported outcomes of PCI on focal (PPG ≥0.66) and diffuse (PPG <0.66) disease.

The endpoints were questionnaires to assess the presence of angina and patient quality of life.

A total of 103 patients were analyzed: 51 had focal disease and 52 had diffuse disease. There were no differences in baseline characteristics between the two groups. The mean PPG was 0.66. Patients with focal disease were treated with fewer (p = 0.022) and shorter (p = 0.015) stents. In addition, this population had higher post-PCI FFR values (p < 0.001) and greater change was observed after intervention (p < 0.001).

Read also: Pulmonary Artery Denervation: Valid Alternative for Pulmonary Arterial Hypertension Grade 1?

After PCI, almost 40% of patients experienced residual angina, which was significantly lower in patients with focal disease compared with diffuse disease (27.5% vs. 51.9%, respectively; p = 0.020). In addition, patients with focal coronary artery disease reported less angina, less physical limitation, and better quality of life.

On the other hand, after PCI, patients with focal disease experienced increased mobility and self-care, and decreased pain and discomfort. There were no differences in the presence of anxiety and/or depression between both groups.

Conclusion

Residual angina after PCI was frequent and found in patients with diffuse coronary disease defined as pre-PCI PPG. After PCI, patients with focal disease experienced angina improvement and better quality of life. PPG was useful to identify patients who would benefit from percutaneous revascularization in terms of symptomatic improvement.

Dr. Andrés Rodríguez.
Member of the editorial board of SOLACI.org.

Original Title: Differential Improvement in Angina and Health-Related Quality of Life After Percutaneous Coronary Interventions in Focal and Diffuse Coronary Artery Disease.

Reference: Carlos Collet, MD, PHD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...